Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2011

View Archived Issues

Studies provide insight into TL-32711 activity and dosing

Phase I trial of Antisense Therapeutics product meets endpoint

Sanofi reports data from GetGoal Duo 1 study

Primary endpoint met in Toviaz trial

International team identifies potential therapeutic for cocaine addiction

Translational profiling of serotonergic neurons reveals new gene linked to autism

Phase II studies evaluate K-134 in peripheral arterial disease

New diacylglycerol O-acyltransferase 1 inhibitors show potential to treat obesity and/or diabetes

New inhibitors of fatty acid synthase presented

U.S. university extracts novel agents with antidiabetic potential from African shrub

Vertex Pharmaceuticals patents novel voltage-gated sodium channel antagonists

Novel immunomodulating and anti-inflammatory compounds described

BioLineRx reports final data from phase Ia BL-1021 trial

Horizon Pharma launches new combination tablet for rheumatoid arthritis and osteoarthritis

Novel GPR119 receptor agonists disclosed by Boehringer Ingelheim

TetraLogic Pharmaceuticals begins new phase I/II TL-32711 trial

Bristol-Myers Squibb divulges new potential therapeutics for hepatitis C

DM-199 increases C-peptide levels in animal model

Morphotek terminates phase III farletuzumab trial

Cyclacel Pharmaceuticals reports interim data from sapacitabine trials

Aradigm obtains U.S. patent for Pulmaquin and plans phase III development

Ono Pharmaceutical announces new launch in Japan

European Commission approves Takeda product for essential hypertension

Theratechnologies discontinues tesamorelin COPD program

ChemoCentryx begins new study of CCX-140 in diabetic nephropathy

FDA committee votes in favor of peginesatide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Flow Neuro wins FDA nod for at-home device for depression
BioWorld MedTech
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...